Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment

Jennifer L Crombie; Philippe Armand

doi:10.1016/j.soc.2019.08.009

Diffuse Large B-Cell Lymphoma and High-Grade B-Cell Lymphoma: Genetic Classification and Its Implications for Prognosis and Treatment

Surg Oncol Clin N Am. 2020 Jan;29(1):115-125. doi: 10.1016/j.soc.2019.08.009.

Authors

Jennifer L Crombie¹, Philippe Armand²

Affiliations

¹ Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. Electronic address: jennifer_crombie@dfci.harvard.edu.
² Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

PMID: 31757308
DOI: 10.1016/j.soc.2019.08.009

Abstract

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is characterized by both clinical and molecular heterogeneity. Despite efforts to tailor therapy for individual patients, treatment remains uniform and a subset of patients have poor outcomes. The past decade has witnessed a dramatic expansion of our understanding of the genomic underpinnings of this disease, especially with the application of next-generation sequencing. In this review, the authors highlight the current genomic landscape of DLBCL and how this information provides a potential molecular framework for precision medicine-based strategies in this disease.

Keywords: Cell of origin; DLBCL; Diffuse large B-cell lymphoma; Genomic classifications; Precision medicine; Targeted therapy.

Publication types

Review